Novel Vaccines Against Transboundary and Emerging Animal Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 259
Special Issue Editor
Interests: African swine fever virus; classical swine fever virus; vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Background
Transboundary and emerging animal diseases (TEADs) are highly contagious or transmissible diseases, with the potential to spread rapidly across the globe and the potential to cause substantial veterinary and socioeconomic consequences. Vaccines are widely recognized as being an essential tool for the control of TAEDs. There is an urgent need for the research and development of safe and efficacious vaccines against TAEDs.
Objectives
This journal issue is devoted to the development, production, laboratory evaluation, and clinical trials of novel vaccines against TAEDs.
Main topics
- Gain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
- Update your knowledge of both existing vaccines and vaccines currently in the research and development stage.
- Get complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
- Analyze the cost-benefit and cost-effectiveness of different vaccine options.
- Make optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
- Stay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.
- Review articles focusing on the development of novel vaccines against TAEDs.
- New-type vaccines against TAEDs.
- Novel vaccine delivery/administration technologies and platforms.
- New adjuvants and immunomodulators.
- Other related topics.
Prof. Dr. Huaji Qiu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
